Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelizumab for Adjuvant Treatment of Esophageal Squamous Cell Cancer
NCT07266480Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Fourth Hospital of Hebei Medical University. Started Sep 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07266480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266480.